Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B I Eriksson

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
The Journal of Bone and Joint Surgery. British Volume|October 31, 2012
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programmeM R Lassen, M Gent, A K Kakkar, et al.
Journal of Thrombosis and Haemostasis : JTH|January 18, 2006
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacementB I Eriksson, L Borris, O E Dahl, et al.
Journal of Thrombosis and Haemostasis : JTH|December 20, 2007
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory studyB I Eriksson, O E Dahl, M R Lassen, et al.
Journal of Thrombosis and Haemostasis : JTH|April 11, 2007
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS studyS M Schellong, J Beyer, A K Kakkar, et al.
The International Journal of Risk & Safety in Medicine|March 21, 2013
Survival in patients undergoing total hip arthroplasty in relation to thromboprophylaxis with low molecular weight heparin: a long-term follow-up studyB S Andersen, H P Jensen, L C Borris, et al.
Journal of Thrombosis and Haemostasis : JTH|October 1, 2004
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic reviewA Y Y Lee, M Gent, J A Julian, et al.
Journal of Thrombosis and Haemostasis : JTH|August 1, 2007
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgeryB I Eriksson, A G G Turpie, M R Lassen, et al.
The Journal of Bone and Joint Surgery. British Volume|May 2, 2009
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacementB I Eriksson, A K Kakkar, A G G Turpie, et al.
The New England Journal of Medicine|November 14, 1997
A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacementB I Eriksson, P Wille-Jørgensen, P Kälebo, et al.
Journal of Thrombosis and Haemostasis : JTH|January 22, 2010
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)B I Eriksson, A G G Turpie, M R Lassen, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
The Journal of Bone and Joint Surgery. British Volume|October 31, 2012
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programmeM R Lassen, M Gent, A K Kakkar, et al.
Journal of Thrombosis and Haemostasis : JTH|January 18, 2006
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacementB I Eriksson, L Borris, O E Dahl, et al.
Journal of Thrombosis and Haemostasis : JTH|December 20, 2007
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory studyB I Eriksson, O E Dahl, M R Lassen, et al.
Journal of Thrombosis and Haemostasis : JTH|April 11, 2007
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS studyS M Schellong, J Beyer, A K Kakkar, et al.
The International Journal of Risk & Safety in Medicine|March 21, 2013
Survival in patients undergoing total hip arthroplasty in relation to thromboprophylaxis with low molecular weight heparin: a long-term follow-up studyB S Andersen, H P Jensen, L C Borris, et al.
Journal of Thrombosis and Haemostasis : JTH|October 1, 2004
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic reviewA Y Y Lee, M Gent, J A Julian, et al.
Journal of Thrombosis and Haemostasis : JTH|August 1, 2007
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgeryB I Eriksson, A G G Turpie, M R Lassen, et al.
The Journal of Bone and Joint Surgery. British Volume|May 2, 2009
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacementB I Eriksson, A K Kakkar, A G G Turpie, et al.
The New England Journal of Medicine|November 14, 1997
A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacementB I Eriksson, P Wille-Jørgensen, P Kälebo, et al.
Journal of Thrombosis and Haemostasis : JTH|January 22, 2010
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)B I Eriksson, A G G Turpie, M R Lassen, et al.
Pageof 8